284 related articles for article (PubMed ID: 34204950)
1.
Jiménez-Mora E; Gallego B; Díaz-Gago S; Lasa M; Baquero P; Chiloeches A
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34204950
[TBL] [Abstract][Full Text] [Related]
2. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells.
Sueda T; Sakai D; Kawamoto K; Konno M; Nishida N; Koseki J; Colvin H; Takahashi H; Haraguchi N; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Satoh T; Doki Y; Mori M; Ishii H
Sci Rep; 2016 Jan; 6():18949. PubMed ID: 26750638
[TBL] [Abstract][Full Text] [Related]
3. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
Choi HJ; Kim TY; Chung N; Yim JH; Kim WG; Kim JA; Kim WB; Shong YK
J Endocrinol; 2011 Oct; 211(1):79-85. PubMed ID: 21795305
[TBL] [Abstract][Full Text] [Related]
4. (V600E)BRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadherin expression through a Snail-dependent mechanism.
Baquero P; Sánchez-Hernández I; Jiménez-Mora E; Orgaz JL; Jiménez B; Chiloeches A
Cancer Lett; 2013 Jul; 335(1):232-41. PubMed ID: 23435375
[TBL] [Abstract][Full Text] [Related]
5. TGFβ induces epithelial-mesenchymal transition of thyroid cancer cells by both the BRAF/MEK/ERK and Src/FAK pathways.
Baquero P; Jiménez-Mora E; Santos A; Lasa M; Chiloeches A
Mol Carcinog; 2016 Nov; 55(11):1639-1654. PubMed ID: 26392228
[TBL] [Abstract][Full Text] [Related]
6. A Combinatorial Strategy for Targeting
Ghosh C; Kumar S; Kushchayeva Y; Gaskins K; Boufraqech M; Wei D; Gara SK; Zhang L; Zhang YQ; Shen M; Mukherjee S; Kebebew E
Clin Cancer Res; 2020 Apr; 26(8):2022-2036. PubMed ID: 31937621
[TBL] [Abstract][Full Text] [Related]
7. c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
Byeon HK; Na HJ; Yang YJ; Kwon HJ; Chang JW; Ban MJ; Kim WS; Shin DY; Lee EJ; Koh YW; Yoon JH; Choi EC
Mol Carcinog; 2016 Nov; 55(11):1678-1687. PubMed ID: 26456083
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
Byeon HK; Na HJ; Yang YJ; Ko S; Yoon SO; Ku M; Yang J; Kim JW; Ban MJ; Kim JH; Kim DH; Kim JM; Choi EC; Kim CH; Yoon JH; Koh YW
Oncotarget; 2017 Jan; 8(1):596-609. PubMed ID: 27880942
[TBL] [Abstract][Full Text] [Related]
9. ADIPOQ/adiponectin induces cytotoxic autophagy in breast cancer cells through STK11/LKB1-mediated activation of the AMPK-ULK1 axis.
Chung SJ; Nagaraju GP; Nagalingam A; Muniraj N; Kuppusamy P; Walker A; Woo J; Győrffy B; Gabrielson E; Saxena NK; Sharma D
Autophagy; 2017 Aug; 13(8):1386-1403. PubMed ID: 28696138
[TBL] [Abstract][Full Text] [Related]
10. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
Mitsiades CS; Negri J; McMullan C; McMillin DW; Sozopoulos E; Fanourakis G; Voutsinas G; Tseleni-Balafouta S; Poulaki V; Batt D; Mitsiades N
Mol Cancer Ther; 2007 Mar; 6(3):1070-8. PubMed ID: 17363500
[TBL] [Abstract][Full Text] [Related]
11. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.
Nucera C; Nehs MA; Nagarkatti SS; Sadow PM; Mekel M; Fischer AH; Lin PS; Bollag GE; Lawler J; Hodin RA; Parangi S
Oncologist; 2011; 16(3):296-309. PubMed ID: 21355020
[TBL] [Abstract][Full Text] [Related]
12. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
13. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.
Salerno P; De Falco V; Tamburrino A; Nappi TC; Vecchio G; Schweppe RE; Bollag G; Santoro M; Salvatore G
J Clin Endocrinol Metab; 2010 Jan; 95(1):450-5. PubMed ID: 19880792
[TBL] [Abstract][Full Text] [Related]
14. Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation.
Conrad WH; Swift RD; Biechele TL; Kulikauskas RM; Moon RT; Chien AJ
Cell Cycle; 2012 Oct; 11(20):3724-30. PubMed ID: 22895053
[TBL] [Abstract][Full Text] [Related]
15. Combination Treatment with the BRAF
Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
[TBL] [Abstract][Full Text] [Related]
16. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.
Chakravarty D; Santos E; Ryder M; Knauf JA; Liao XH; West BL; Bollag G; Kolesnick R; Thin TH; Rosen N; Zanzonico P; Larson SM; Refetoff S; Ghossein R; Fagin JA
J Clin Invest; 2011 Dec; 121(12):4700-11. PubMed ID: 22105174
[TBL] [Abstract][Full Text] [Related]
17. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
18. BRAF V600E-dependent role of autophagy in uveal melanoma.
Zhao Y; Wang W; Min I; Wyrwas B; Moore M; Zarnegar R; Fahey TJ
J Cancer Res Clin Oncol; 2017 Mar; 143(3):447-455. PubMed ID: 27928645
[TBL] [Abstract][Full Text] [Related]
19. Betulinic acid induces autophagy-dependent apoptosis via Bmi-1/ROS/AMPK-mTOR-ULK1 axis in human bladder cancer cells.
Zhang Y; He N; Zhou X; Wang F; Cai H; Huang SH; Chen X; Hu Z; Jin X
Aging (Albany NY); 2021 Sep; 13(17):21251-21267. PubMed ID: 34510030
[TBL] [Abstract][Full Text] [Related]
20. Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.
Preto A; Gonçalves J; Rebocho AP; Figueiredo J; Meireles AM; Rocha AS; Vasconcelos HM; Seca H; Seruca R; Soares P; Sobrinho-Simões M
BMC Cancer; 2009 Oct; 9():387. PubMed ID: 19878585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
